Published 11 November 2026. We'll update this page if the MHRA changes its UK advice.
In short: on 9 November 2026, the US Food and Drug Administration (FDA) told the makers of every GLP-1 medicine to add a warning about NAION to their labels. NAION is a rare eye condition that can cause sudden vision loss. The warning covers Mounjaro, Wegovy, Ozempic, the Wegovy pill and Foundayo. The risk is very small: about 6 cases per 100,000 people per year of treatment, compared with about 4 per 100,000 in people not taking these medicines. In the UK, the MHRA already lists NAION as a very rare side effect of semaglutide (Wegovy and Ozempic). The FDA decision is a US labelling change, not a new UK rule. Don't stop your treatment because of the headlines. Know the symptoms, and talk to your prescriber if you're worried.
What did the FDA announce?
On Monday 9 November 2026, the FDA issued a Drug Safety Communication. It requires the makers of all GLP-1 receptor agonist medicines to add information about NAION to the "Warnings and Precautions" section of their US labels.
It applies to the whole class, including:
- Tirzepatide: Mounjaro (Zepbound in the US)
- Semaglutide: Wegovy injection, the Wegovy pill, Ozempic and Rybelsus
- Orforglipron: Foundayo
- Older GLP-1 medicines such as liraglutide (Saxenda, Victoza), dulaglutide (Trulicity) and exenatide
The FDA said NAION cases have been reported with every GLP-1 medicine currently on the market, so it chose a class-wide warning rather than naming individual drugs.
What is NAION?
NAION stands for non-arteritic anterior ischemic optic neuropathy. It happens when blood flow to the front of the optic nerve, which connects the eye to the brain, is reduced. Damage to the nerve can cause:
- sudden, painless loss of vision, usually in one eye, often noticed on waking
- blurred or cloudy vision
- a dark area or blind spot, often in the upper or lower half of what you see
- colours looking dull or washed out
The vision loss can be permanent. NAION is uncommon in the general population and is more likely in people over 50 and in people with diabetes, high blood pressure, sleep apnoea, anaemia, kidney disease, or a history of smoking. Many of these conditions are also common in people taking weight loss medicines, which makes it harder to measure how much risk comes from the medicine itself.
How big is the risk?
Very small, but probably real.
| Source | What it found |
|---|---|
| FDA analysis of 126 clinical trials (134,000+ people) | 6.4 NAION cases per 100,000 people per year on a GLP-1, against 3.8 per 100,000 on placebo or other diabetes medicines. That's roughly 2–3 extra cases per 100,000 people per year. |
| European Medicines Agency (June 2025, semaglutide) | About 1 extra case per 10,000 people treated for a year, based mainly on studies in people with type 2 diabetes. Classed as a "very rare" side effect. |
| MHRA (February 2026, semaglutide) | Agreed NAION is a very rare side effect, affecting up to 1 in 10,000 people taking semaglutide. |
Put another way: if 10,000 people take a GLP-1 medicine for a year, most estimates suggest somewhere between none and one extra person will develop NAION because of it. The evidence is mixed. The FDA's trial analysis rested on just 15 probable cases, and it found no biological explanation in animal studies. Some large real-world studies found a clear link, especially with semaglutide, and others found little or no extra risk. The strongest signal so far has been with semaglutide. The FDA has taken a cautious approach by applying the warning to the whole class.
What's the position in the UK?
- Semaglutide (Wegovy, Ozempic and Rybelsus): the MHRA updated UK product information in February 2026 to list NAION as a very rare side effect. Its advice is to stop semaglutide if NAION is confirmed. The Wegovy pill, licensed in June 2026, contains the same medicine, so the same advice applies.
- Mounjaro and Foundayo: UK product information doesn't currently list NAION. In February 2026, the MHRA said it was reviewing the evidence for other GLP-1 medicines. As of 11 November 2026, it hasn't announced a change following the FDA decision. We'll update this page if it does.
- The FDA warning doesn't change UK rules on its own. UK labels are set by the MHRA. Regulators often reach similar conclusions, though, so a UK update for the wider class is possible.
- The other current UK warning is about unlicensed medicines. Retatrutide ("reta") isn't licensed anywhere, so anything sold under that name is illegal and unverified: what the warnings mean and how to check a seller.
I'm taking Mounjaro, Wegovy or a weight loss pill. What should I do?
- Don't stop suddenly because of the news. For most people, the benefits of treatment are much larger than this very small risk. If you're worried, speak to your prescriber or the pharmacy that supplies your medicine before making changes.
- Know the warning signs. If you notice sudden loss of vision, or part of your vision, in one eye, treat it as urgent. The MHRA advises going to eye casualty (if there's one near you) or A&E straight away. Don't wait for it to clear.
- Tell any doctor or optician that you're on a weight loss medicine. If you buy it privately, it may not appear on your GP record, so they won't know unless you tell them.
- Mention your history. If you've had NAION or other optic nerve problems before, tell your prescriber at your consultation. The FDA notes that people who've had NAION before are at higher risk of it happening again.
- Keep up with regular eye tests, especially if you have diabetes. A rapid improvement in blood sugar can temporarily worsen existing diabetic eye disease (retinopathy), which is a separate issue from NAION.
- Report suspected side effects through the MHRA Yellow Card scheme (yellowcard.mhra.gov.uk or the Yellow Card app).
Does this change which medicine I should choose?
Not on its own. The FDA applied the same warning to every GLP-1 medicine, and the absolute risk is very low for all of them. Choosing between Mounjaro, Wegovy and the pills is still a decision for you and a prescriber, based on how well each works for you, side effects, how you prefer to take it, and cost. A good provider should ask about your eye history and other health conditions at your consultation. If they don't, that's worth noting.
Only use providers registered with the General Pharmaceutical Council (GPhC) or the Care Quality Commission (CQC), so that you get a proper consultation, genuine medicine and follow-up support. Compare regulated UK providers.
Frequently asked questions
Does Mounjaro cause blindness? NAION has been reported in people taking Mounjaro and other GLP-1 medicines, and it can cause permanent vision loss in one eye. It's very rare: the FDA's figures suggest roughly 2–3 extra cases per 100,000 people per year of treatment across the whole class. Mounjaro's UK product information doesn't currently list NAION.
Is Wegovy safe for my eyes? For the vast majority of people, yes. UK regulators list NAION as a very rare side effect of semaglutide, affecting up to 1 in 10,000 people. Know the symptoms and act fast if your vision suddenly changes.
Does the warning apply to the Wegovy pill and Foundayo? Yes. The FDA warning covers all GLP-1 medicines, including oral semaglutide (the Wegovy pill) and orforglipron (Foundayo). See our guide to Foundayo side effects.
Should I stop my weight loss injection? Not without talking to your prescriber. Stopping can lead to weight regain and, if you have diabetes, worse blood sugar control. Stop and seek urgent help only if you develop sudden vision loss.
Has the MHRA issued a new warning? Not yet, as of 11 November 2026. The MHRA's current advice dates from February 2026 and covers semaglutide only. It has said it is reviewing other GLP-1 medicines.
Keep reading
Sources: FDA Drug Safety Communication on GLP-1 receptor agonists and NAION (9 November 2026); MHRA Drug Safety Update, "Semaglutide (Wegovy, Ozempic and Rybelsus): risk of NAION" (5 February 2026); European Medicines Agency PRAC conclusion on semaglutide and NAION (June 2025).
This article is general information, not medical advice. If you have sudden changes in your vision, seek urgent medical help. For questions about your own treatment, speak to your prescriber or pharmacist.



